Daniel D. Christensen, MD
Clinical Professor of Psychiatry and Neurology
Adjunct Professor of Pharmacology Director, Brain Bank
University Neuropsychiatric Institute
University of Utah
Salt Lake City, Utah
Peter J. Lin, MD
Director of Primary Care Initiatives
Canadian Heart Research Center
Nurses and NPs: 2.4 Medium
Alzheimer’s disease (AD), the incidence of which is expected to double before the mid-century mark, may be reliably diagnosed and managed in primary care. Evidence indicates, however, that AD is substantially under-recognized in this setting. Symptoms of AD are often present for two years or more before a diagnosis is made, according to one report. Reasons that have been suggested for this are time constraints within a busy primary care practice, and a focus on medical problems over attention to neurological issues.
Early diagnosis benefits both AD patients and family members. With early diagnosis, treatment can be initiated at a time when the chances are best for improving or slowing cognitive declines, declines in global functioning and activities of daily living, and behavior.
This program addresses many of the myriad issues surrounding recognition and diagnosis of Alzheimer’s disease in primary care. Provided are tools and recommendations for implementing standard screening of patients at highest risk for AD – patients aged 65 and older – and study data on use of available treatments. Program Developer/Facilitator
. Target Audience
This program has been designed for physicians, nurses and nurse practitioners with an interest in the management of Alzheimer’s disease.
Upon completion of this educational activity, the participant should be able to:
Demonstrate an awareness of Alzheimer's disease signs, symptoms, and possible presentations in a Primary Care Practice (PCP) setting
Describe a structured approach to identifying patients at high risk for Alzheimer's disease within the context of delivery of primary care
Recommend pharmacologic treatments for Alzheimer's disease based on randomized clinical trial data and risks and benefits of each agent and drug class
Discuss guidelines for referral of patients to specialist care
Review educational and support services that are available to Alzheimer's disease patients, caregivers, and families
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Daniel D. Christensen, MD, discloses that he has received consulting fees as a member of speakers bureaus and advisory committees for Pfizer Inc, and has received research support from Pfizer Inc, Novartis and Forest Pharmaceuticals, Inc.
Peter J. Lin, MD discloses that he has received consulting fees as a member of speakers bureaus for Pfizer Inc, Eisai Inc., Janssen Pharmaceutica, Inc., and Novartis and as a member of advisory committees for Pfizer Inc, Eisai Inc., and Janssen Pharmaceutica, Inc.
This educational activity may contain discussion of published and/or investigational uses of agents for the treatment of Alzheimer’s disease. Some uses of these agents have not been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AKH Inc. is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. Provider #030803. AKH Inc. designates this educational activity for 2.4 contact hours.
AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. AKH Inc. designates this educational activity for 2.4 contact hours.
Physician Assistants: AAPA accepts Category I CME credit for the PRA from organizations accredited by ACCME. All programs on cmecorner.com which carry ACCME Category I CME credit are acceptable towards the PA Category I (Preapproved) CME requirement.
PAs requesting credit should check the “Other” box on the post-test. Commercial Support Statements
This program was made possible by an educational grant from Eisai and Pfizer Neuroscience.
This activity is best viewed with a high speed/broadband internet connection.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program. It will also instruct you to turn off all pop-up blockers.
Clicking on "start the program" on this screen will bring you to the lobby or main program menu where you can begin the program with a topic overview by clicking on the "Auditorium" doors.
Upon completion of the topic overview, please click on the doors to "Patient Services" where you will participate in three interactive case studies. The two sections of the program will take approximately 120 minutes to complete. Upon completion of the program, click on the post-test button to access the CME/CE post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CE certificate.
The opinions expressed in this activity are those of the faculty consultants and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., Eisai, or Pfizer Neuroscience. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.